Imunon, Inc. (IMNN) Earnings Call Transcripts
Imunon, Inc.'s Latest Earnings Call - Q4 FY2025
Imunon, Inc. reported its fourth quarter and full year 2025 financial results on March 31, 2026, showcasing strong momentum in its pivotal Phase III OVATION 3 trial for IMNN-001, an IL-12 immunotherapy targeting advanced ovarian cancer. The company highlighted a significant improvement in overall survival data from the OVATION 2 study, now at 14.7 months, which positions IMNN-001 as a potential game-changer in frontline treatment. The net loss for 2025 was $14.5 million, a notable reduction from $18.6 million in 2024, reflecting improved cost management. Management maintained guidance for enrolling 80 patients in the OVATION 3 trial within the next 12 months, signaling confidence in the trial's progress and future regulatory approval prospects.
Reported metrics
| Metric | Value |
|---|---|
| Net Loss | $14.5M (positive) |
| Overall Survival Benefit (OVATION 2) | 14.7 months (positive) |
| R&D Expenses | $7.8M (positive) |
| Cash and Cash Equivalents | $8.8M (neutral) |
| Patient Enrollment Target (OVATION 3) | 80 patients (positive) |
Guidance from management
Management maintained guidance to enroll 80 patients in the OVATION 3 trial within the next 12 months, indicating confidence in trial progress and future milestones.
What management said
So it's obviously very early. We just released the data last week. We are participating tomorrow in the MedInvest Biotech & Pharma Investor Conference, and we are getting new inquiries that are occurring even as of this week. But I expect that to continue to develop. These kinds of partnerships, whether they're geographic in nature or they're more fundamental with big pharma really ultimately has to fit with a strate...
It's possible. I think that it will ultimately depend really on the -- our interactions with the study PI, [ Dr. Amir Jazaeri. ] We know that he presented data that was very exciting to see the analytical data, and he decided to really take a cohort of patients and analyze them together rather than continuing to analyze patients over time, individual patients over time. And the clinical data, of course, will be con...
What analysts pressed on
Analysts expressed concerns about the competitive landscape, particularly regarding potential new therapies that could emerge before OVATION 3 data is available. There were also questions about the pace of enrollment and how it might be impacted by external factors in the oncology space.
Main topics on the call
- Overall Survival Improvement — The final analysis of the OVATION 2 study revealed a median overall survival benefit of 14.7 months, an increase from 13 months previously reported. Dr. Stacy Lindborg emphasized, "this unprecedented Phase II results hav...
- Phase III Trial Enrollment — Enrollment for the OVATION 3 trial is ahead of plan, with 7 clinical sites actively enrolling patients and an additional 43 sites under evaluation. Management stated, "patient randomization and treatment in the Phase III...
- Cost Management and Financial Discipline — Imunon reported a net loss of $14.5 million for 2025, down from $18.6 million in 2024, due to disciplined cash management and reduced R&D expenses. CFO Jeff Church noted, "Research and development expenses for 2025 were ...
- Regulatory Pathway Confidence — The FDA's endorsement of overall survival as the primary endpoint for the OVATION 3 trial enhances confidence in the regulatory approval process. Dr. Lindborg stated, "OVATION 3 continues to derisk the path to a potentia...
Read the full Imunon, Inc. transcript (Q4 FY2025) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Imunon, Inc.
Imunon, Inc. (IMNN) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqCM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 33 calls on record spanning March 26, 2020 to August 11, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 33 Imunon, Inc. earnings call transcripts on record, spanning March 26, 2020 to August 11, 2026. Based on this history, Imunon, Inc. reports quarterly. The most recent call on file is dated August 11, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- IMNN
- Exchange
- NasdaqCM
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 33
- First call
- March 26, 2020
- Most recent
- August 11, 2026
- Reporting cadence
- quarterly